On April 24, 2026, JP Morgan initiated coverage of Hims & Hers Health (NYSE:HIMS) with an “Overweight” recommendation, despite an average one-year price target of $25.34 per share, indicating a potential 17.06% decrease from the current price of $30.55.
The projected annual revenue for Hims & Hers Health is estimated at $1.205 billion, representing a significant 48.67% decline, while the projected non-GAAP EPS stands at -$0.20. Institutional ownership has dropped by 21.59% over the past quarter, with 182,887K shares currently held by institutions.
Key shareholders include JP Morgan with 18,838K shares (8.58% ownership), Capital World Investors with 14,323K shares (6.52% ownership), and Goldman Sachs Group with 10,347K shares (4.71% ownership), all reporting changes in their portfolio allocations in the last quarter.
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
